Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Shuo Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3517-8971; OpenAlex author ID A5043622621. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers

Papers 8

  1. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  2. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12885-023-11181-x↗
  3. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  4. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  5. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12885-021-08380-9↗
  6. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  7. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Co-author DOI 10.1038/s41416-019-0704-2↗
  8. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2019.11.009↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suizhi Gao · 8 shared papers, 2019–2023 · strength 1.01
  2. Shiwei Guo · 8 shared papers, 2019–2023 · strength 1.01
  3. Xiaohan Shi · 8 shared papers, 2019–2023 · strength 1.01
  4. Guoxiao Zhang · 6 shared papers, 2021–2023 · strength 0.81
  5. Gang Jin · 6 shared papers, 2019–2023 · strength 0.72
  6. Xiaoyi Yin · 5 shared papers, 2021–2023 · strength 0.71
  7. Bo Li · 5 shared papers, 2020–2023 · strength 0.63
  8. Kailian Zheng · 4 shared papers, 2021–2023 · strength 0.52
  9. Xiongfei Xu · 4 shared papers, 2020–2023 · strength 0.46
  10. Lingyu Zhu · 3 shared papers, 2023 · strength 0.45
  11. Zhuo Shao · 3 shared papers, 2020–2023 · strength 0.34
  12. Jing Shen · 3 shared papers, 2019–2021 · strength 0.30
  13. Jian Wang · 2 shared papers, 2023 · strength 0.29
  14. Gang Li · 2 shared papers, 2021–2022 · strength 0.23
  15. Gang Y Jin · 1 shared paper, 2023 · strength 0.16
  16. Hui Jiang · 1 shared paper, 2023 · strength 0.16
  17. Bin Song · 1 shared paper, 2023 · strength 0.13
  18. Peng Cheng · 1 shared paper, 2023 · strength 0.13
  19. Xiangui Hu · 1 shared paper, 2022 · strength 0.13
  20. Bo Li · 1 shared paper, 2022 · strength 0.13
  21. Gang Jin · 1 shared paper, 2022 · strength 0.13
  22. Tianlin He · 1 shared paper, 2022 · strength 0.13
  23. Wei Jing · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.